Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard‐of‐Care Management of Systemic Lupus Erythematosus in Canada

  • Published on 07/05/2024
  •  Reading time: 6 min.

Zahi Touma 1, Sheena Kayaniyil 2, Anna Parackal 2, Denisse Bonilla 1, Jiandong Su 1, Christina Qian 3, Sally D. Miller 3, Adam Johnston 4, James Gahn 4, Erik D. Hille 4, Robert Ohsfeldt 5, Shelly Chandran 2

1 Toronto Western Hospital Toronto Ontario Canada
2 AstraZeneca Mississauga Ontario Canada
3 Broadstreet Health Economics & Outcomes Research Vancouver British Columbia Canada
4 Medical Decision Modeling Inc. Indianapolis Indiana
5 Medical Decision Modeling Inc., Indianapolis, Indiana, and Texas A&M School of Public Health College Station


Objective Our objective was to describe the administration of glucocorticoids (GCs) and characterize its association with organ damage in a longitudinal systemic lupus erythematosus (SLE) cohort over a time period spanning the introduction of biologics in Canada.
Methods A retrospective observational study was conducted using data from a large SLE cohort in Canada, including adults without lupus nephritis or central nervous system lupus. Patients were...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Rheumatology

Receive our newsletter to stay up to date with the latest news in Rheumatology